These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29146119)

  • 1. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis.
    Davidson MB; Pan D
    Diabetes Res Clin Pract; 2018 Jan; 135():102-110. PubMed ID: 29146119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
    He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
    Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
    Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
    JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence.
    Davidson MB
    J Diabetes Complications; 2016 Aug; 30(6):981-5. PubMed ID: 27133452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone use and the risk of bladder cancer.
    Kuo HW; Tiao MM; Ho SC; Yang CY
    Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
    Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
    Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
.
    Li Z; Sun M; Wang F; Shi J; Wang K
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):210-219. PubMed ID: 28025963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit.
    Ryder RE
    Diabet Med; 2015 Mar; 32(3):305-13. PubMed ID: 25472014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
    Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.
    Lee MY; Hsiao PJ; Yang YH; Lin KD; Shin SJ
    PLoS One; 2014; 9(1):e85479. PubMed ID: 24427312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
    Lewis JD; Ferrara A; Peng T; Hedderson M; Bilker WB; Quesenberry CP; Vaughn DJ; Nessel L; Selby J; Strom BL
    Diabetes Care; 2011 Apr; 34(4):916-22. PubMed ID: 21447663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
    Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
    Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
    BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone and bladder cancer: a population-based study of Taiwanese.
    Tseng CH
    Diabetes Care; 2012 Feb; 35(2):278-80. PubMed ID: 22210574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
    Colmers IN; Bowker SL; Majumdar SR; Johnson JA
    CMAJ; 2012 Sep; 184(12):E675-83. PubMed ID: 22761478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
    Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
    Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
    Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
    Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.